{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"description":"Number of participants with Dose Limiting Toxicities (DLT) in Cycle 1 (escalation part to determine MTD) is presented .","groups":[{"description":"Patients were intravenously administered escalating dose of volasertib 250 milligram (mg) (Volasertib (BI 6727), solution for infusion) on Day 1+15 (28-day cycle) combined with subcutaneous administration of Azacitidine (powder for reconstitution of an injection suspension) 75 milligram / square meter (mg/m2) once daily on Days 1 to 7 (28- day cycle)","id":"OG000","title":"Volasertib 250 mg + Azacitidine (Escalation Cohort)-Part 1"},{"description":"Patients were intravenously administered escalating dose of volasertib 300 mg (Volasertib (BI 6727), solution for infusion) on Day 1+15 (28-day cycle) combined with subcutaneous administration of Azacitidine (powder for reconstitution of an injection suspension) 75 mg/m2 once daily on Days 1 to 7 (28-day cycle)","id":"OG001","title":"Volasertib 300 mg + Azacitidine (Escalation Cohort)- Part 1"},{"description":"Patients were intravenously administered escalating dose of volasertib 170 mg/m2 (Volasertib (BI 6727), solution for infusion) on Day 7 combined with subcutaneous administration of Azacitidine (powder for reconstitution of an injection suspension) 75 mg/m2 once daily on Days 1 to 7 (28-day cycle)","id":"OG002","title":"Volasertib 170 mg/m2 + Azacitidine (Escalation Cohort)- Part 2"},{"description":"Patients were intravenously administered escalating dose of volasertib 110 mg/m2 (Volasertib (BI 6727), solution for infusion) on Day1 and Day 7 combined with subcutaneous administration of Azacitidine (powder for reconstitution of an injection suspension) 75 mg/m2 once daily on Days 1 to 7 (28-day cycle)","id":"OG003","title":"Volasertib 110 mg/m2 + Azacitidine (Escalation Cohort)- Part 2"}],"paramType":"NUMBER","populationDescription":"MTD set","reportingStatus":"POSTED","timeFrame":"4 weeks","title":"Number of Participants With Dose Limiting Toxicities (DLT) in Cycle 1","type":"PRIMARY","unitOfMeasure":"participants"}